Do drugs reduce utilisation of other healthcare resources?

PharmacoEconomics

Volumn 25, Issue 3, 2007, Pages 209-221

  Crémieux, Pierre Yves ^a   Ouellette, Pierre ^b   Petit, Patrick ^c  

^a ANALYSIS GROUP   (United States)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; CANADA; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DRUG COSTS; FEMALE; FORECASTING; HEALTH CARE RATIONING; HEALTH RESOURCES; HUMANS; LIFE EXPECTANCY; MALE;

EID: 33847751469     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725030-00004     Document Type: Article

References (26)

1. Canadian Institute for Health Information. Dépenses de santé-Macro-dépenses [online]. Available from URL: http://secure.cihi.ca/cihiweb/dispPage.jsp?.cw_page= statistics_results_topic_macrospend_f&cw_topic=Dé penses%20de%20santé&cw_subtopic=Macro-dépenses [Accessed 2004 Feb 26]
2. Patented Medicine Price Review Board. Analyse de géné rateurs de côuts des régimes d'assurance-médicaments provinciaux - Ontario [online]. Available from URL: http://www.pmprb-cepmb.gc. ca/CMFiles/on-f14HCK-492003-7143.pdf [Accessed 2004 Feb 26]
3. Morgan S. Drug spending in Canada: recent trends and causes. Med Care 2004 Jul; 42 (7): 635-42
4. Morgan S. Drug expenditure trends in the Canadian provinces: magnitude and causes from 1998 to 2004. HealthCare Policy 2005; 1 (1): 85-99
5. Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Working paper 9754. National Bureau of Economic Research, 2003 [online]. Available from URL: http://www.nber.org/papers/w9754 [Accessed 2004 Jun 25]
6. Organisation for Economic Co-operation and Development. OECD health data 2006: frequently requested data [online]. Available from URL: http://www.oecd.org/document/60/0,2340,fr_2825_495642_32368700_1_1_1_1,00.html [Accessed 2004 Oct 6]
7. Lichtenberg FR. The benefits and costs of newer drugs: evidence from the 1996 Medical Expenditure Panel Survey. Working paper 8147. Cambridge (MA): National Bureau of Economic Research, 2001 [online]. Available from URL: http://www.nber.org/papers/w8147 [Accessed 2004 Jun 25)
8. Crémieux PY, Meilleur MC, Petit P, et al. Public and private pharmaceutical spending as determinants of health outcomes in Canada. J Health Econ 2005; 14 (2): 107-16
9. Statistics Canada [online]. Available from URL: http://www40.statcan.ca/ index.htm [Accessed 2007 Feb 14]
10. Taylor RS, Drummond MF, Salkeld G, et al. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004; 329 (7472): 972-5
11. Pirttili T, van Baelen B, Kavanagh S. Effect of galantamine on time to residential or nursing home admission: an international study. Poster presented at the 17th European Congress of Neuropsychopharmacology; 2004 Oct 9-13; Stockholm
12. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Circulation 1996; 93: 1796-802
13. Taylor DM, Wright T, Libretto SE. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS): UK Investigator Group. J Clin Psychiatry 2003; 64 (5): 589-97
14. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin: a clinical and economic appraisal. Pharmacoeconomics 1995; 8 (2): 91-9
15. Eisenberg JM, Koffer H, Finkler SA. Economic analysis of a new drug: potential savings in hospital operating costs from the use of a once-daily regimen of a parenteral cephalosporin. Rev Infect Dis 1984; 6 Suppl. 4: S909-23
16. Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: results from the managed-care outcomes project. Am J Manag Care 1996; 2 (3): 253-64
17. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug payment limits on admission to hospitals and nursing homes. N Engl J Med 1991; 325 (15): 1072-7
18. Cutler M, McClellan M. Is technological change in medicine worth it? Health Aff 2001; 20 (5): 11-29
19. Lichtenberg FR. Benefits and costs of newer drugs: an update. Working paper 8996. Cambridge (MA): National Bureau of Economic Research, 2002 [online]. Available from URL: http://www.nber.org/papers/w8996 [Accessed 2004 Jun 25]
20. Gardner C, Arya N, McAllister ML. Can a health unit take action on the determinants of health? Can J Public Health 2005 Sep-Oct; 96 (5): 374-9
21. Cicutto L, Murphy S, Coutts D, et al. Breaking the access barrier: evaluating an asthma center's efforts to provide education to children with asthma in schools. Chest 2005 Oct; 128 (4): 1928-35
22. Felder S, Meier M, Schmitt M. Health care expenditure in the last months of life. J Health Econ 2000; 19: 679-95
23. Johnson D, Yong J. Costly ageing or costly deaths? Understanding health care expenditures using Australian Medicare payments data. Aust Econ Pap 2006; 45 (1): 57-74
24. Canadian Institute for Health Information. National health expenditure trends 1975-2004 [online]. Available from URL: http://dsp-psd.tpsgc.gc.ca/ Collection/H118-2-2004E.pdf (Accessed 2007 Apr 13)
25. Doran T, Whitehead M. Do social policies and political context matter for health in the United Kingdom? Int J Health Serv 2003; 33 (3): 495-522
26. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. Obstet Gynecol Surv 2005 Sep; 60 (9): 593-5